MCID: VRL010
MIFTS: 56

Viral Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Viral Hepatitis

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 55 3 15 72 33
Hepatitis, Viral, Animal 44 72
Animal Viral Hepatitis 12 17
Viral Hepatitis with Hepatic Coma 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 44 D006524
UMLS 72 C0019194 C0042721

Summaries for Viral Hepatitis

CDC : 3 Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to non-a-e hepatitis and epstein-barr virus hepatitis. An important gene associated with Viral Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Human cytomegalovirus infection. The drugs Atorvastatin and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are Reduced mammosphere formation and cellular

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

Wikipedia : 75 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 618)
# Related Disease Score Top Affiliating Genes
1 non-a-e hepatitis 33.6 F2 ALB
2 epstein-barr virus hepatitis 33.2 F2 ALB
3 acute liver failure 33.2 SLC17A5 GPT F2 ALB
4 hepatitis c 33.1 TNF IFNA2 IFNA1 GPT GGT1
5 hepatitis d 32.8 IFNA2 GPT F2
6 hepatitis a 32.5 TNF SERPINA1 SEPSECS GPT F2 ALB
7 hepatic coma 31.9 GPT F2 ALB
8 cholecystitis 31.3 GPT F2 ALB
9 fatty liver disease 31.2 TNF SLC17A5 GGT1 FAS
10 hepatitis e 31.1 TNF GPT F2 CD40LG ALB
11 typhoid fever 31.1 TNF F2 ALB
12 opisthorchiasis 31.1 TNF GPT AFP
13 portal hypertension 31.0 TNF GPT F2 ALB
14 hepatic encephalopathy 31.0 TNF SLC17A5 GPT F2 ALB
15 leptospirosis 30.8 TNF TLR2 F2
16 cryoglobulinemia, familial mixed 30.7 IFNA2 IFNA1 CD40LG
17 proteasome-associated autoinflammatory syndrome 1 30.7 TNF TLR2 ALB
18 autoimmune disease 30.7 TNF IFNA1 FAS CD40LG
19 acquired immunodeficiency syndrome 30.7 TNF IFNA2 IFNA1 ALB
20 obstructive jaundice 30.6 TNF SLC17A5 GPT GGT1 F2 ALB
21 alcoholic liver cirrhosis 30.6 SLC17A5 F2 ALB AFP
22 autoimmune hepatitis 30.6 SEPSECS GPT GGT1 FAS F2
23 sclerosing cholangitis 30.6 TNF GGT1 ALB
24 vasculitis 30.5 TNF SERPINA1 IFNA2 CD40LG
25 meningitis 30.5 TNF TLR2 ALB
26 gastroenteritis 30.5 TNF IFNA1 ALB
27 aplastic anemia 30.5 TNF HFE FASLG FAS ALB
28 peritonitis 30.5 TNF TLR2 F2 ALB
29 schistosomiasis 30.4 TNF F2 CD40LG ALB
30 alcoholic hepatitis 30.4 TNF SLC17A5 GPT F2 ALB
31 alpha-1-antitrypsin deficiency 30.4 SERPINA1 HFE ALB
32 hepatitis 30.4 TNF SLC17A5 SEPSECS IFNA2 IFNA1 GPT
33 protein-energy malnutrition 30.4 TNF GPT ALB
34 cholangitis 30.4 TNF GPT GGT1 F2 ALB
35 hepatitis b 30.3 TNF SLC17A5 IFNA2 IFNA1 GPT GGT1
36 graft-versus-host disease 30.3 TNF FASLG FAS
37 infective endocarditis 30.3 TNF TLR2 F2
38 esophageal varix 30.3 F2 ALB AFP
39 eclampsia 30.2 TNF F2 ALB
40 liver cirrhosis 30.2 SLC17A5 SERPINA1 IFNA1 HFE GPT GGT1
41 endocarditis 30.2 TNF TLR2 F2 ALB
42 biliary atresia 30.1 MX1 GPT ALB
43 hellp syndrome 30.1 SLC17A5 GPT F2
44 infantile liver failure syndrome 1 30.1 SLC17A5 GPT F2 ALB
45 respiratory failure 30.1 TNF SERPINA1 ALB
46 wilson disease 29.9 HFE GPT F2 ALB
47 biliary tract disease 29.9 GGT1 F2 ALB AFP
48 cholangitis, primary sclerosing 29.9 SEPSECS GPT GGT1 ALB
49 hepatocellular carcinoma 29.9 SERPINA1 IFNA1 HFE GGT1 FASLG F2
50 scrub typhus 29.9 TNF TLR2 SLC17A5 GPT

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ABCB7 ALB CD40LG FAS FASLG G6PD
2 homeostasis/metabolism MP:0005376 10.1 ABCB7 AFP ALB CD40LG F2 FAS
3 digestive/alimentary MP:0005381 9.87 ALB F2 FAS FASLG HFE TLR2
4 mortality/aging MP:0010768 9.8 ABCB7 AFP ALB CD40LG F2 FAS
5 liver/biliary system MP:0005370 9.76 ABCB7 AFP ALB FAS FASLG HFE
6 skeleton MP:0005390 9.28 CD40LG F2 FAS FASLG GGT1 GPT

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 301)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
3
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
6
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
7
Halofantrine Approved Phase 4 69756-53-2 37393
8
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
9
Lopinavir Approved Phase 4 192725-17-0 92727
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
15
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
16
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
17
Ribavirin Approved Phase 4 36791-04-5 37542
18
Nevirapine Approved Phase 4 129618-40-2 4463
19
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
20
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
21
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
22
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
24
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
25
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
26
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
27
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
28 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
29 Anticholesteremic Agents Phase 4
30 Interferon alpha-2 Phase 4
31 Interferon-alpha Phase 4
32 Reverse Transcriptase Inhibitors Phase 4
33 Nucleic Acid Synthesis Inhibitors Phase 4
34 Anti-HIV Agents Phase 4
35 interferons Phase 4
36 Vitamin D2 Phase 4
37 Ergocalciferols Phase 4
38 Calciferol Phase 4
39 Calcium, Dietary Phase 4
40 Bone Density Conservation Agents Phase 4
41 HIV Fusion Inhibitors Phase 4
42 Dihydroxycholecalciferols Phase 4
43 Hypoglycemic Agents Phase 4
44 Hormone Antagonists Phase 4
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
46 Dextrans Phase 4
47 Iron-Dextran Complex Phase 4
48 Plasma Substitutes Phase 4
49 Anticoagulants Phase 4
50 Blood Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 279)
# Name Status NCT ID Phase Drugs
1 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
2 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
4 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
5 A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus Completed NCT01327547 Phase 4 Maraviroc;Placebo
6 Efficacy of Silymarin for Treatment of Acute Hepatitis In Egypt: A Randomized, Double-Blinded, Controlled Trial Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
7 Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro) Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
8 Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL Completed NCT02039362 Phase 4 Tenofovir DF
9 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
10 A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
11 A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
12 Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
13 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
14 Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests Completed NCT01600105 Phase 4 Perfusion MRI
15 Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4 Theragran Hematinic;low molecular weight iron dextran
16 A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent. Completed NCT00866021 Phase 4 Lopinavir/ritonavir;Lopinavir/ritonavir with two nucleoside analogs
17 Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects Completed NCT00125775 Phase 4
18 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
19 Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China Completed NCT01340950 Phase 4 zidovudine-lamivudine-nevirapine;tenofovir-lamivudine-efavirenz
20 Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study) Completed NCT03499639 Phase 4 Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
21 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
22 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
23 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
24 Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial Recruiting NCT03933384 Phase 4 Tenofovir alafenamide;Entecavir
25 Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection: an Open-label Randomized Clinical Trial Recruiting NCT03854630 Phase 4 Engerix-B
26 An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
27 Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam Enrolling by invitation NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
28 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Not yet recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
29 Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters Not yet recruiting NCT02973295 Phase 4 Silymarin
30 RiFL:Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
31 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
32 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
33 Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24 Unknown status NCT00336518 Phase 3 peginterferon alfa-2a;ribavirin
34 A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study Unknown status NCT02173951 Phase 2, Phase 3 Deferiprone
35 Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy Unknown status NCT02215525 Phase 3
36 Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life Completed NCT01008293 Phase 2, Phase 3 VSL#3;Lactulose
37 Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
38 A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
39 A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment Completed NCT01595685 Phase 3 Telbivudine;Entecavir
40 Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy Completed NCT02060058 Phase 3 Stop trial intervention for boceprevir, PEG-IFN and RBV
41 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
42 Health Promotion and Public Safety: Community-based Collaborative Services to Addicted Offenders Completed NCT01843751 Phase 3 buprenorphine/naloxone
43 Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C Completed NCT00001729 Phase 3 Ribavirin
44 Proton Beam Radiotherapy Versus Switching Control Radiofrequency Ablation for Patients With Medium (>3, ≦5 cm) or Large (>5, ≦7cm) Treatment-naive Hepatocellular Carcinoma Recruiting NCT02640924 Phase 3
45 Growth Hormone Therapy and Its Effect on Nitrogen Metabolism and Malnutrition in Liver Cirrhosis Recruiting NCT03420144 Phase 2, Phase 3 Standard Medical Therapy;Growth Hormone
46 Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Patients With Advanced Hepatocelluler Carcinoma Recruiting NCT02568748 Phase 3
47 Granulocyte Colony Stimulating Factor Therapy In Decompensated Cirrhosis Of Liver: A Double Blinded Single Centre Randomised Controlled Trial Recruiting NCT03911037 Phase 2, Phase 3 G-CSF;Placebo
48 RECURRENCE RATE OF HEPATOCELLULAR CARCINOMA AFTER TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH DIRECT ACTING ANTIVIRALS: RANDOMIZED CONTROLLED PHASE 3 TRIAL (CAUTIOUS TRIAL) Recruiting NCT03551444 Phase 3 Administration of DAA-based treatment
49 Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) Active, not recruiting NCT01135056 Phase 3 Sorafenib tosylate
50 Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial Active, not recruiting NCT03327155 Phase 3 Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

41
Liver, Testes, T Cells, Kidney, Bone, Thyroid, Bone Marrow

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 17688)
# Title Authors PMID Year
1
Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. 9 38
20155784 2010
2
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 9 38
19330428 2010
3
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 9 38
19769633 2009
4
Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. 9 38
19252365 2009
5
Bicyclol: a novel drug for treating chronic viral hepatitis B and C. 9 38
19149648 2009
6
Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. 9 38
19103527 2008
7
Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. 9 38
18801734 2008
8
Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. 9 38
19034238 2008
9
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. 9 38
18422961 2008
10
Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. 9 38
18671818 2008
11
Significant correlation between surgical stress of hepatectomy and changes in the serum levels of HGF, IL-6 and soluble Fas in patients with viral hepatitis. 9 38
18795698 2008
12
Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. 9 38
18498412 2008
13
Natural anticoagulants and fibrinolytic activity following interferon therapy in chronic viral hepatitis. 9 38
18469546 2008
14
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. 9 38
18307594 2008
15
The role of interleukin-22 in hepatitis C virus infection. 9 38
18191408 2008
16
Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. 9 38
18167134 2008
17
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. 9 38
17919273 2008
18
Hyperferritinemia in the Chinese and Asian community: a retrospective review of the University of British Columbia experience. 9 38
18209779 2008
19
HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population. 9 38
17573946 2007
20
Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha. 9 38
18019713 2007
21
[A close relationship between viral hepatitis B and Toll-like receptor 2]. 9 38
17669234 2007
22
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. 9 38
17589934 2007
23
High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. 9 38
17498256 2007
24
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. 9 38
17439526 2007
25
[Two cases of hyperthyroidism induced by interferon-alpha therapy for renal cell carcinoma]. 9 38
17515071 2007
26
Modafinil's use in combating interferon-induced fatigue. 9 38
17318387 2007
27
Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. 9 38
17148690 2007
28
Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. 9 38
17274827 2007
29
[Some aspects of human mineral metabolic disturbances in viral hepatitis of various genesis]. 9 38
17436703 2007
30
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. 9 38
17192324 2007
31
Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. 9 38
17328497 2007
32
[Interferon therapy in chronic viral hepatitis; an autoimmunity dilemma]. 9 38
17941466 2007
33
[Utility of analytical parameters in the diagnosis of liver disease]. 9 38
17373869 2007
34
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. 9 38
17075991 2006
35
Molecular detection of transfusion transmitted virus coinfection with some hepatotropic viruses. 9 38
17076531 2006
36
An official ATS statement: hepatotoxicity of antituberculosis therapy. 9 38
17021358 2006
37
Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. 9 38
16858074 2006
38
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. 9 38
16702862 2006
39
Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. 9 38
16776568 2006
40
Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. 9 38
16530290 2006
41
Expression of oxidative stress-related molecules in circulating leukocytes and urine in patients with chronic viral hepatitis. 9 38
16448453 2006
42
Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. 9 38
16498048 2006
43
Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. 9 38
16429839 2006
44
A novel panel of blood markers to assess the degree of liver fibrosis. 9 38
16317693 2005
45
[Progress of the study on the relationship between MxA and interferon therapy of viral hepatitis]. 9 38
16381656 2005
46
Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. 9 38
16227290 2005
47
Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. 9 38
16437596 2005
48
Iron in nonhemochromatotic liver disorders. 9 38
16315139 2005
49
[Alanine aminotransferase is a substitute marker of viral hepatitis]. 9 38
16408624 2005
50
Typhoid fever and viral hepatitis in a G6PD deficient individual. 9 38
16599045 2005

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 TNF TLR2 IFNA2 IFNA1 FASLG FAS
2
Show member pathways
12.84 TNF TLR2 IFNA2 IFNA1 FASLG FAS
3
Show member pathways
12.65 TNF IFNA2 IFNA1 FASLG FAS CD40LG
4
Show member pathways
12.53 TNF TLR2 MX1 IFNA2 IFNA1 FASLG
5
Show member pathways
12.49 TNF TLR2 FASLG FAS CD40LG
6
Show member pathways
12.21 TNF GGT1 F2 ALB
7 12.16 TNF TLR2 FASLG FAS
8
Show member pathways
12.13 TNF IFNA2 IFNA1 FASLG FAS
9 12.09 TNF FASLG FAS CD40LG
10 12.06 TNF TLR2 IFNA2 IFNA1
11
Show member pathways
11.98 TNF TLR2 FASLG FAS
12
Show member pathways
11.64 TNF FASLG CD40LG
13 11.61 TNF TLR2 IFNA1 FASLG FAS CD40LG
14
Show member pathways
11.59 TNF IFNA2 IFNA1 FASLG FAS
15 11.38 TNF FASLG FAS
16 11.34 TNF TLR2 CD40LG
17 11.22 TNF FASLG FAS
18 11.19 F2 ALB AFP
19 11.07 TNF FASLG FAS
20 10.8 GPT G6PD

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 SERPINA1 GPT GGT1 G6PD FGL2 FASLG
2 extracellular region GO:0005576 9.7 TNF SERPINA1 IFNA2 IFNA1 FGL2 FASLG
3 endoplasmic reticulum lumen GO:0005788 9.67 SERPINA1 F2 ALB AFP
4 membrane raft GO:0045121 9.62 TNF TLR2 FASLG FAS
5 external side of plasma membrane GO:0009897 9.55 TNF HFE FASLG F2 CD40LG
6 extracellular space GO:0005615 9.4 TNF SERPINA1 IFNA2 IFNA1 HFE GPT

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.86 TNF IFNA2 IFNA1 FASLG
2 cellular protein metabolic process GO:0044267 9.81 SERPINA1 F2 ALB AFP
3 blood coagulation GO:0007596 9.76 SERPINA1 IFNA2 IFNA1 F2
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.72 TNF FASLG FAS
5 B cell differentiation GO:0030183 9.71 IFNA2 IFNA1 CD40LG
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.7 TNF FASLG CD40LG
7 type I interferon signaling pathway GO:0060337 9.67 MX1 IFNA2 IFNA1
8 apoptotic signaling pathway GO:0097190 9.65 TNF FASLG FAS
9 defense response GO:0006952 9.62 TNF MX1 IFNA2 IFNA1
10 humoral immune response GO:0006959 9.61 TNF IFNA2 IFNA1
11 leukotriene metabolic process GO:0006691 9.57 TLR2 GGT1
12 extrinsic apoptotic signaling pathway GO:0097191 9.54 TNF FASLG FAS
13 acute-phase response GO:0006953 9.43 SERPINA1 HFE F2
14 regulation of immunoglobulin secretion GO:0051023 9.4 TNF CD40LG
15 immune response GO:0006955 9.35 TNF TLR2 FASLG FAS CD40LG
16 B cell proliferation GO:0042100 9.33 IFNA2 IFNA1 CD40LG
17 necroptotic signaling pathway GO:0097527 8.8 TNF FASLG FAS

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 TNF TLR2 SERPINA1 MX1 G6PD FAS
2 tumor necrosis factor receptor binding GO:0005164 9.13 TNF FASLG CD40LG
3 cytokine activity GO:0005125 9.02 TNF IFNA2 IFNA1 FASLG CD40LG

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....